Literature DB >> 12871268

Hemophilia: treatment options in the twenty-first century.

P M Mannucci1.   

Abstract

In the last three decades, hemophilia has moved from the status of a neglected and often fatal hereditary disorder to that of a fully defined group of molecular-pathological entities for which safe and effective treatment is available. Hemophilia is likely to be the first widespread severe genetic condition to be cured by gene therapy in the third millennium. In the socio-economic arena it remains a challenge to humanity to know that four-fifths of the world's hemophiliacs still receive no treatment at all. Production of factor (F) VIII and IX in the milk of transgenic farmyard animals could provide a source of less expensive replacement therapy for developing countries. Affordable gene transfer will be the ultimate solution for hemophilia in the third world as in the first. Thus it may be confidently predicted that the early new millennium will see an end to this ancient scourge.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871268     DOI: 10.1046/j.1538-7836.2003.00262.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  20 in total

1.  Thrombin generation and bleeding in haemophilia A.

Authors:  K E Brummel-Ziedins; M F Whelihan; M Gissel; K G Mann; G E Rivard
Journal:  Haemophilia       Date:  2009-06-26       Impact factor: 4.287

Review 2.  The modern treatment of haemophilia: a narrative review.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

3.  Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loop.

Authors:  S R Selvaraj; A N Scheller; H Z Miao; R J Kaufman; Steven W Pipe
Journal:  J Thromb Haemost       Date:  2012-01       Impact factor: 5.824

4.  Cardiac tamponade in a patient with moderate hemophilia A and factor VIII Inhibitors.

Authors:  Nina Ghosh; Patrick Teefy; Lori Laudenbach; Georges-Etienne Rivard
Journal:  Can J Cardiol       Date:  2006-01       Impact factor: 5.223

5.  In vivo efficacy of platelet-delivered, high specific activity factor VIII variants.

Authors:  Teshell K Greene; Cheng Wang; Jessica D Hirsch; Li Zhai; Jamie Gewirtz; Michael A Thornton; Hongzhi Z Miao; Steven W Pipe; Randal J Kaufman; Rodney M Camire; Valder R Arruda; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2010-09-17       Impact factor: 22.113

6.  Design and characterization of an APC-specific serpin for the treatment of hemophilia.

Authors:  Stéphanie G I Polderdijk; Ty E Adams; Lacramioara Ivanciu; Rodney M Camire; Trevor P Baglin; James A Huntington
Journal:  Blood       Date:  2016-10-27       Impact factor: 22.113

7.  Haemophilia B is clinically less severe than haemophilia A: further evidence.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2016-10-04       Impact factor: 3.443

Review 8.  Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide.

Authors:  K E Van Cott; P E Monahan; T C Nichols; W H Velander
Journal:  Haemophilia       Date:  2004-10       Impact factor: 4.287

Review 9.  Empirical and theoretical phenotypic discrimination.

Authors:  K E Brummel-Ziedins; T Orfeo; F R Rosendaal; A Undas; G E Rivard; S Butenas; K G Mann
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

Review 10.  The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A.

Authors:  Tristan Knight; Michael U Callaghan
Journal:  Ther Adv Hematol       Date:  2018-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.